EL7.AI
StocksMediumUpdated•Originally published 11 September 2026•Updated 11 September 2026•
2 min read

Bayer’s Up-to-$7.25 Billion Roundup Deal Heads to Sept. 14 Final-Approval Hearing

Key Facts

1The proposed settlement provides up to $7.25 billion of funding, with a final-approval hearing on September 14, 2026.
2The payment plan spans as many as 21 years and targets current and future Roundup claims involving alleged non-Hodgkin lymphoma.
3The Supreme Court's June 25, 2026, ruling held that federal law preempts failure-to-warn claims based on Roundup's EPA-approved label.
4Bayer said litigation provisions and liabilities would rise from €7.8 billion to €11.8 billion, with approximately €5 billion of payouts estimated for 2026.
5BAYRY closed at $14.07 on September 10, 2026, within a daily range of $14.06 to $14.20.

A nationwide class settlement proposed by Bayer subsidiary Monsanto, with funding of up to $7.25 billion, faces a final-approval hearing in the Circuit Court of the City of St. Louis, Missouri, on September 14, 2026. The court granted preliminary approval on March 4, 2026, but the agreement does not become final without judicial approval.

The settlement targets current and future claims alleging non-Hodgkin lymphoma from Roundup use through a long-term claims program. Monsanto plans to fund the program with declining, capped annual payments over as many as 21 years, and the agreement contains no admission of liability or wrongdoing.

On August 27, 2026, the 8th U.S. Circuit Court of Appeals dismissed a challenge seeking to move the settlement dispute into federal court, leaving the approval process before the Missouri state court. Objectors can still present their arguments at the final-approval hearing, and subsequent appeals may remain possible.

The hearing follows the U.S. Supreme Court's June 25, 2026, decision in Monsanto v. Durnell, which held that federal pesticide law preempts a state failure-to-warn claim when the Environmental Protection Agency does not require the warning on the label. The ruling concerns a specific legal theory, while the settlement seeks to address a broader set of current and future claims involving alleged non-Hodgkin lymphoma.

The figures show why the matter is financially significant for Bayer. The company said the settlements and litigation costs would increase litigation provisions and liabilities from €7.8 billion to €11.8 billion, including an increase in the glyphosate-related amount from €6.5 billion to €9.6 billion. It estimated approximately €5 billion of litigation-related payouts in 2026 and expected negative free cash flow for the year.

BAYRY closed at $14.07 on September 10, 2026, after trading as high as $14.20 and as low as $14.06. The next measurable developments are the court's decision following the September 14, 2026, hearing and any implementation conditions or appeals; approval would advance the settlement but would not guarantee the elimination of every Roundup-related legal risk.